Ten-year experience with endovascular therapy in aortic aneurysms11No competing interests declared.

INTRODUCTION Endoluminal treatment of aneurysms has emerged as a potential therapeutic alternative since its introduction in 1991. Although initial and midterm results of endoluminal aneurysm exclusion are very encouraging, late adverse events still represent a big limitation for the widespread use of the technique. In order to obtain information about the longterm results, we retrospectively reviewed the data available of thirty consecutive patients followed for more than five years after the endoluminal treatment of abdominal aortic aneurysms (AAA) using the home-made Parodi Endograft (PE). In addition, prospectively gathered information of 136 consecutive patients treated using the Vanguard Endograft (Boston Scientific Corp, Natick, MA) was analyzed. Only midterm results (mean 28 months, range 7 to 53 months) were available for evaluation in the latter group (VE). The information served as a base of comparison with the results of the PE group.